期刊文献+

炎症性心肌病20例临床分析 被引量:1

Clinical analysis of twenty cases of inflammatory cardiomyopathy
下载PDF
导出
摘要 目的探讨炎症性心肌病的临床特点。方法收集20例炎症性心肌病患儿的病史、体格检查及随访资料,对比分析患儿治疗前后的心电图、胸部X片、超声心动图及心功能测定等变化。结果 20例炎症性心肌病患儿,发病年龄2岁3个月~11岁8个月,随访8个月~3年3个月。患儿在患病前1~4周均有感染史,临床表现为咳嗽、胸闷、气促和心音低钝,实验室检查主要为炎性指标升高,超声心动图示左房左室大、室壁运动幅度减低和左室射血分数降低,心电图示ST-T改变和期前收缩,胸部X线摄片为肺淤血和心脏扩大。经过治疗,临床痊愈2例,好转11例,2例病情无变化,死亡3例,失访2例。结论炎症性心肌病可发生于任何年龄,临床表现为急/慢性心功能不全,预后较好,部分可治愈。 Objective To explore the clinical features of inflammatory cardiomyopathy. Methods The detailed history, physical examination, and follow-up data in 20 children with inflammatory cardiomyopathy were examined. Comparison was made with electrocardiogram, X-ray, echocardiography and cardiac function before and after treatments. Results The age at onset ranged from 2.25 to 11.67 years in 20 children with inflammatory cardiomyopathy. They all had a history of 1 - 4 weeks of infection. Clinical symptoms included cough, chest distress, and polypnea, the examina- tion revealed cardiac enlargement, reduced left ventricular ejection fraction and elevated laboratory inflammatory markers. After treatment, 2 children recovered, 11 improued 2 had no changes, 3 died of heart failure, and 2 lost. The clinical cure rate was 10%, the improvement rate was 55%, and the mortality was 15%. Conclusions The inflammatory cardiomyopathy occurs at any age, and manifests symptoms of acute/chronic heart failure in clinic. With comprehensive treatments, natients had satisfactory nro^nosis and some recovered completely.
出处 《临床儿科杂志》 CAS CSCD 北大核心 2012年第7期613-615,共3页 Journal of Clinical Pediatrics
关键词 炎症性心肌病 心功能不全 心肌损伤 inflammatory cardiomyopathy cardiac insufficiency myocardial injury
  • 相关文献

参考文献9

  • 1Maisch B, Richter A, Koelsch S, et al. Management of patients with suspected (peri-) myocarditis and inflamma- tory dilated cardiomyopathy [J]. Herz,2006,31 (9): 881-890.
  • 2Castellano G, Affuso F, Di Conza P, et al. Myocarditis and dilated cardiomyopathy: possible connections and treatments [J]. J Cardiovasc Med (Hagerstown),2008,9 (7) :666-671.
  • 3Maisch B, Richter A, Sandmoller A, et al. Inflammatory dilated cardiomyopathy (DCMI) [J]. Herz,2005,30 (6) : 535-544.
  • 4BeliavskiI EA, Zykov KA, Narusov OIu, et al. Inflamma- tory eardiomyopathy : state-of-the-art E J ]. Ter Arkh, 2010, 82(8) :62-71.
  • 5Kallwellis-Opara A, Dorner A, Poller WC, et al. Auto- immunological features in inflammatory cardiomyopathy[J]. Clin Res Cardiol,2007,96(7) :469-480.
  • 6Kania G, Blyszczuk P, Eriksson U. Mechanisms of cardiac fibrosis in inflammatory heart disease [J]. Trends Cardio- vasc Med,2009,19(8) :247-252.
  • 7Schultheiss HP, Kuhl U. Overview on chronic viral cardio- myopathy/chronic myocarditis [Ji. Ernst Schering Res Found Workshoo, 2006, (55) : 3-18.
  • 8Volz HC, Kaya Z, Katus HA, et al. The role of HMGB1/ RAGE in inflammatory cardiomyopathy [J]. Semin Thromb Hemost,2010,36(2) : 185-194.
  • 9Mller K, Klingel K, Kaiser U, et al. Immunsuppressive therapy in virus-negative eosinophilic inflammatory cardio- myopathy [J ]. Dtsch Med Wochenschr,2011,136 (16) : 816-819.

同被引文献19

  • 1Schultheiss HP,Noutsias M. Inflammatory cardiomyopathy (DCMi):pathogenesi s an d therapy[M].Springer-Verlag,2010.201-225.
  • 2Richardson P,Mckenna W,Bristow M. Report of the 1995 World Health Organization/international society and federation of cardiology task force on the definition and classification of cardiomyopathies[J].Circulation,1996,(05):841-842.
  • 3Maisch B,Pankuweit S. Current treatment options in (peri) myocarditis and inflammatory cardiomyopathy[J].Herz,2012,(06):644-656.
  • 4Maron BJ,Towbin JA,Thiene G. Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Council on Clinical Cardiology,Heart Failure and Transplantation Committee ;Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups;and Council on Epidemiology.and Prevention[J].Circulation,2006,(14):1807-1816.
  • 5Maisch B,Richter A,Sandm(o)ller A. Inflammatory dilated cardiomyopathy (DCMI)[J].Herz,2005,(06):535-544.
  • 6Portig I,Wilke A,Freyland M. Familial inflammatory dilated cardiomyopathy[J].European Journal of Heart Failure,2006,(08):816-825.doi:10.1016/j.ejheart.2006.02.010.
  • 7Abston ED,Coronado M J,Bucek A. TLP3 deficiency induces chronic inflammatory cardiomyopathy in resistant mice following coxsackievirus B3 infection:role for IL-4[J].American Journal of Physiology-Regulatory Integrative and Comparative Physiology,2013,(04):R267-R277.
  • 8Escher F,Vetter R,Kühl U. Fractalkine in human inflammatory cardiomyopathy[J].Heart,2011,(09):733-739.
  • 9Klingel K,Sauter M,Bock CT. Molecular pathology of inflammatory cardiomyopathy[J].Medical Microbiology and Immunology,2004,(2-3):101-107.
  • 10Bobbert P,Scheibenbogen C,Jenke A. Adiponectin expression in patients with inflammatory cardiomyopathy indicates favourable outcome and inflammation control[J].European Heart Journal,2011,(09):1134-1147.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部